Research Article
Analysis of Serum IgG1 to Predict Progression and Therapeutic Effect in Patients with Multiple Myeloma
Table 3
Concentration of serum monoclonal proteins in patients with multiple myeloma.
| | | Decreased N (%) | Normal N (%) | Increased N (%) |
| | IgA (N = 560; range: 0.82–4.52 g/L) | 351 (62.68) | 125 (22.32) | 84 (15) | | IgG (N = 560; range: 7.51–15.6 g/L) | 204 (36.43) | 171 (30.54) | 185 (33.04) | | IgM (N = 560; range: 0.46–3.04 g/L) | 381 (68.04) | 168 (30.00) | 11 (1.96) | | IgG1 (N = 345; range: 4.05–10.11 mg/ml) | 134 (38.84) | 120 (34.78) | 91 (26.38) | | IgG2 (N = 345; range: 1.69–7.86 mg/ml) | 196 (56.81) | 128 (37.10) | 21 (6.09) | | IgG3 (N = 345; range: 0.11–0.85 mg/ml) | 119 (34.49) | 198 (57.39) | 28 (8.12) | | IgG4 (N = 345; range: 0.03–2.01 mg/ml) | 31 (8.99) | 298 (86.38) | 16 (4.64) |
|
|
